If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-02. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Major (Gurkha Commissioned Officer) Lilbahadur Gurung (513800), Queen's Gurkha Signals. Major Lester Andrew Holley (505640), The Royal Gurkha Rifles. Major Anthony Lovell Jackson (509141), Royal Regiment of Artillery. Acting Major John Frederick Kemp (486467), Kent Army Cadet Force, Territorial Army. 24011748 Warrant Officer Class 2 Christopher Keogh, Royal Regiment of Artillery. 24256499 Corporal of Horse Ian Kirkpatrick, The Life Guards. Major Robert Scott Lawther (520854), The Royal Irish Regiment. Major Philip John Leighton (509537), The Green Howards. Major Allan Charles LeQuelenec (520025), Royal Army Medical Corps. Major Richard Allen Licence (530853), Royal Corps of Signals. Major Simon Jonathan Alun Lloyd (499742), Royal Regiment of Artillery. 24435856 Warrant Officer Class 2 John MacKinnon, Corps of Royal Engineers. Lieutenant Colonel Donald Anderson MacLean (Retired). Acting Lieutenant Colonel Peter David Marsden (473626), Monkton Combe School Combined Cadet Force, Territorial Army. 24335098 Warrant Officer Class 1 Terence George Morrissey, Adjutant General's Corps (SPS). Lieutenant Stuart Joseph Nye (546430), The Princess of Wales's Royal Regiment. 24853206 Lance Corporal (Acting Corporal) Derrick Anthony O'Connor, Corps of Royal Engineers. 24413672 Colour Sergeant Stuart Owen Oliver, The Royal Regiment of Fusiliers. Lieutenant (Acting Captain) Nigel Derek Partington (546198), Royal Army Medical Corps. Captain (Acting Major) Brian William Pitchforth (537833), The Parachute Regiment. 24256052 Warrant Officer Class 1 Joseph Thomas Preece, The Light Dragoons.
Recent evidence has shown that smoking tobacco increases the release of dopamine in the brain, specifically in the mesolimbic pathway, the same neuro-reward circuit activated by addictive substances such as heroin and cocaine. This suggests nicotine use has a pleasurable effect that triggers positive reinforcement. One study found that smokers exhibit better reaction-time and memory performance compared to non-smokers, which is consistent with increased activation of dopamine receptors. Neurologically, rodent studies have found that nicotine self-administration causes lowering of reward thresholds—a finding opposite that of most other addictive substances (e.g., cocaine and heroin). The carcinogenity of tobacco smoke is not explained by nicotine per se, which is not carcinogenic or mutagenic, although it is a metabolic precursor for several compounds which are. In addition, it inhibits apoptosis, therefore accelerating existing cancers. Also, NNK, a nicotine derivative converted from nicotine, can be carcinogenic. The addictive potential of nicotine is increased after co-administration of a MAOI, which specifically causes sensitization of the locomotor response in rats, a measure of addictive potential.
DNA binding site prediction on protein DNA the Double Helix Game From the official Nobel Prize web site DNA under electron microscope Dolan DNA Learning Center Double Helix: 50 years of DNA, Nature Proteopedia DNA Proteopedia Forms_of_DNA ENCODE threads explorer ENCODE home page at Nature Double Helix 1953–2003 National Centre for Biotechnology Education Genetic Education Modules for Teachers – DNA from the Beginning Study Guide PDB Molecule of the Month DNA "Clue to chemistry of heredity found". The New York Times, June 1953. First American newspaper coverage of the discovery of the DNA structure DNA from the Beginning Another DNA Learning Center site on DNA, genes, and heredity from Mendel to the human genome project. The Register of Francis Crick Personal Papers 1938 – 2007 at Mandeville Special Collections Library, University of California, San Diego Seven-page, handwritten letter that Crick sent to his 12-year-old son Michael in 1953 describing the structure of DNA. See Crick's medal goes under the hammer, Nature, 5 April 2013.
Sources: en.wikipedia.org
Following the contested 2006 presidential election, Felipe Calderón initiated Operation Michoacán, a militarized campaign against drug cartels as an effort to consolidate political authority, strengthen the legitimacy of his administration, and rally public support. Often described as the first major campaign of the conflict, Operation Michoacán marked the beginning of large-scale confrontations between government forces and drug cartels, eventually involving about 45,000 troops together with state and federal police. Calderón's government pioneered a militarized "kingpin strategy" that relied on Mexican Army and Federal Police deployments to capture or kill cartel leaders. This security approach was led by Genaro García Luna (Secretariat of Public Security), Eduardo Medina Mora (Attorney General of Mexico), and Guillermo Galván Galván (Secretariat of National Defense). Early operations included Operation Baja California, Operation Sinaloa, and Operation Chihuahua. Although drug-related violence spiked markedly in contested areas along the U.S. border, such as Ciudad Juárez, Tijuana, and Matamoros, the government was initially successful in detaining and killing high-ranking cartel members, including Alfredo Beltrán Leyva, Arturo Beltrán Leyva, Ignacio Coronel Villarreal, Antonio Cárdenas Guillén, and Vicente Carrillo Leyva. Calderón expressed that the cartels seek "to replace the government" and "are trying to impose a monopoly by force of arms, and are even trying to impose their own laws".
It will detect, on the TLC plate, virtually all amines, carbamates and also, after vigorous heating, amides. Upon reaction with ninhydrin, amino acids undergo decarboxylation. The released CO2 originates from the carboxyl carbon of the amino acid. This reaction has been used to release the carboxyl carbons of bone collagen from ancient bones for stable isotope analysis in order to help reconstruct the palaeodiet of cave bears. Release of the carboxyl carbon (via ninhydrin) from amino acids recovered from soil that has been treated with a labeled substrate demonstrates assimilation of that substrate into microbial protein. This approach was successfully used to reveal that some ammonium oxidizing bacteria, also called nitrifying bacteria use urea as a carbon source in soil.
Muscle weakness Difficulty walking (ambulation is typically lost by age 5–15 years) Contractures Characteristically, bilateral contractures of the proximal joints of the upper extremities (shoulder and elbows) and proximal joints of the lower extremities (hips and knees). Spine contractures in the form of progressive scoliosis occurs and occasionally contracture of neck musculature also known as torticollis. Joint looseness Contractures can be associated with distal joint laxity of the upper extremities (wrists and fingers) and of the lower extremities (ankle and toes). Fatty infiltration of muscle
== Book chapters == 1. Richoz O, Hafezi F Modifications for Thin Corneas, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 51–55. 2. Hafezi F, Mavrakanas N Corneal Collagen Cross-Linking for Postoperative Corneal Ectasia, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 75–81. 3. Pajic B, Latinovic S, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Fankhauser F Lamellar corneal resection with LDV Crystal line femtosecond laser after penetrating keratoplasty, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 4. Pajic B, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Mueller J, Pajic D, Fankhauser F Applanation-free femtosecond laser processing of the cornea, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 5. Iseli HP, Hafezi F, Mrochen M, Seiler T Estado actual de la reticulación del colágeno corneal, in Técnicas de modelado corneal: desde la ortoqueratologia hasta el cross-linking, Cezón Prieto J, Editor. 2009, Sociedad Española de Cirurgia Ocular Implanto-Refractiva: Madrid. 381–86. 6. Hafezi F, Iseli HP, Seiler T Automated anterior lamellar keratoplasty for the management of complications in refractive surgery, in Surgical techniques in anterior and posterior lamellar corneal surgery, John T, Editor. 2005, Slack Inc.: New York. (in press). 7.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.